fbpx

Year

2013
You can now apply for fellowships
  . Leading US centers in food allergy will be involved in an NIH-funded CoFAR study, coordinated by Dr. Sampson and Dr. Jones in collaboration with DBV’ team. CoFAR6 study will help to better characterize the mechanisms of action of epicutaneous immunotherapy DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new approach...
This Proof of concept study aims to capitalize on DBV’s safe and non-invasive technology and Inserm’s unique expertise to address refractory Hemophilia A, a severe orphan disease with no cost-effective and convenient treatment today available to patients DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies,...
Stallergenes to exercise option to develop and commercialize a birch allergy new product DBV eligible for milestone payments and royalties on Stallergenes’ net sale Stallergenes acquires an equity position in DBV Stallergenes S.A. (Euronext Paris: GENP), worldwide leader in allergen immunotherapy, and DBV Technologies (Euronext Paris: DBV), creator of Viaskin® for the treatment of allergies,...
  Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that it has appointed Michael Narachi as Chairman of the Board of Directors. Michael currently serves as President and Chief Executive Officer of Orexigen Therapeutics, Inc. Michael has 29 years...
  The Independant Data and Safety Monitoring Board (DSMB) recommends VIPES continuation without modifications DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today its topline financial results for first nine months 2013 and provided a clinical update on VIPES (Viaskin Peanut’s Efficacy and Safety),...
Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces positive results from its Phase II study of APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients. The study showed that APD515 significantly reduced the symptoms of dry mouth (the primary endpoint) compared to placebo. APD515 is...
Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC”) relating to the proposed initial public offering of its common stock. All shares...
Additional Financing Validates Unique Orphan Drug Accelerator Model Cydan, LLC, an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, today announced that the company has expanded its initial round of financing, bringing its total financing raised to $26 million. Cydan launched in April 2013 with a $16 million financing from...
No safety concerns and reduction in cardiovascular events observed through three years of follow up in the MYDICAR high dose group. Celladon Corporation, a clinicalstage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced the full three year long-term follow up results from Phase...
1 2 3 4 7

News

Seven research institutions receive DKK 20 million for coronavirus research
1. April 2020
How we handle changes to research projects in light of the coronavirus pandemic
31. March 2020
Lundbeck Foundation gives its first coronavirus grant to trial with a known drug
26. March 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge